Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHM03 in Adult Patients With Upper Limb Spasticity
NCT06584240Phase 2Completed
- Sponsor
- Junhemeng Biopharmaceutical
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised trial of JHM03 in Upper limb spasticity (5 arms), sponsored by Junhemeng Biopharmaceutical. Primary endpoints: Incidence rate of adverse events and severe adverse events at 12 weeks and Change from baseline for primary targeted muscle group on the Modified Ashworth Scale (MAS) at 4 weeks. Started Sep 2024; status: completed.
02
Drugs
JHM03
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT06584240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584240.